SiBone $SIBN Shares Sold by Impax Asset Management Group plc

Impax Asset Management Group plc lowered its holdings in shares of SiBone (NASDAQ:SIBN) by 9.8% during the 2nd quarter, Holdings Channel reports. The fund owned 691,761 shares of the company’s stock after selling 75,000 shares during the period. Impax Asset Management Group plc’s holdings in SiBone were worth $13,019,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd acquired a new position in SiBone during the 1st quarter valued at about $34,000. Virtus Advisers LLC bought a new position in shares of SiBone in the first quarter valued at approximately $58,000. Corton Capital Inc. acquired a new position in shares of SiBone during the second quarter valued at approximately $189,000. Quantbot Technologies LP acquired a new position in shares of SiBone during the first quarter valued at approximately $158,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in SiBone during the first quarter worth approximately $162,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Anshul Maheshwari sold 2,601 shares of the company’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $18.33, for a total transaction of $47,676.33. Following the completion of the sale, the chief financial officer directly owned 208,533 shares of the company’s stock, valued at approximately $3,822,409.89. This represents a 1.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey W. Dunn sold 80,000 shares of the firm’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $18.95, for a total value of $1,516,000.00. Following the completion of the sale, the director directly owned 10,307 shares in the company, valued at approximately $195,317.65. This represents a 88.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 120,021 shares of company stock worth $2,141,872 in the last 90 days. 4.00% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Cantor Fitzgerald set a $25.00 target price on SiBone and gave the stock an “overweight” rating in a report on Monday, August 11th. Wall Street Zen cut shares of SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of SiBone in a research note on Wednesday, October 8th. Finally, Truist Financial decreased their price target on shares of SiBone from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $23.00.

SiBone Trading Down 4.1%

NASDAQ SIBN opened at $17.26 on Friday. SiBone has a twelve month low of $11.70 and a twelve month high of $20.05. The company has a debt-to-equity ratio of 0.21, a quick ratio of 7.00 and a current ratio of 7.97. The stock has a market cap of $748.91 million, a price-to-earnings ratio of -33.84 and a beta of 0.81. The firm’s 50 day moving average price is $15.30 and its two-hundred day moving average price is $16.60.

SiBone (NASDAQ:SIBN) last released its earnings results on Monday, November 10th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.05. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%.The company had revenue of $48.66 million for the quarter, compared to analysts’ expectations of $46.67 million. SiBone has set its FY 2025 guidance at EPS. Equities analysts anticipate that SiBone will post -0.78 EPS for the current year.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.